CVKD
NASDAQ · Pharmaceuticals
Cadrenal Therapeutics Inc
$6.52
-0.45 (-6.46%)
Financial Highlights (FY 2025)
Revenue
2.07M
Net Income
662.5K
Gross Margin
35.1%
Profit Margin
32.0%
Rev Growth
+2.5%
D/E Ratio
0.18
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 35.1% | 35.1% | 35.1% |
| Operating Margin | 38.1% | 42.2% | 35.0% |
| Profit Margin | 32.0% | 31.3% | 24.1% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.07M | 2.13M | 1.91M |
| Gross Profit | 727.3K | 746.7K | 671.2K |
| Operating Income | 790.3K | 897.5K | 669.9K |
| Net Income | 662.5K | 666.1K | 461.6K |
| Gross Margin | 35.1% | 35.1% | 35.1% |
| Operating Margin | 38.1% | 42.2% | 35.0% |
| Profit Margin | 32.0% | 31.3% | 24.1% |
| Rev Growth | +2.5% | +18.2% | +2.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.76M | 1.83M | 1.72M |
| Total Equity | 9.55M | 9.25M | 9.23M |
| D/E Ratio | 0.18 | 0.20 | 0.19 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 955.8K | 1.01M | 1.06M |
| Free Cash Flow | 570.9K | 515.8K | 427.8K |